Serum Amyloid a Predicts Prognosis and Chemotherapy Efficacy in Patients with Advanced Pancreatic Cancer

References

• Prashanth R, Tagore S, Vinaya G. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol. 2019;10:10–27. doi:10.14740/wjon1166
   PubMedGoogle Scholar
• Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371:2140–2141. doi:10.1056/NEJMra1404198
   PubMed Web of Science ®Google Scholar
• Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–2406. doi:10.1056/NEJMoa1809775
   PubMed Web of Science ®Google Scholar
• Zhan HX, Xu JW, Wu D, et al. Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies. Cancer Med. 2017;6:1201–1219. doi:10.1002/cam4.1071
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–1825. doi:10.1056/NEJMoa1011923
   PubMed Web of Science ®Google Scholar
• Ishii N, Nishikawa H, Iwata Y, et al. Proposal of predictive model on survival in unresectable pancreatic cancer receiving systemic chemotherapy. J Cancer. 2020;11:1223–1230. doi:10.7150/jca.38861
   PubMedGoogle Scholar
• Tsai S, George B, Wittmann D, et al. Importance of normalization of CA19-9 levels following neoadjuvant therapy in patients with localized pancreatic cancer. Ann Surg. 2020;271:740–747. doi:10.1097/SLA.0000000000003049
   PubMedGoogle Scholar
• Azizian A, Rühlmann F, Krause T. CA19-9 for detecting recurrence of pancreatic cancer. Sci Rep. 2020;10:1332. doi:10.1038/s41598-020-57930-x
   PubMed Web of Science ®Google Scholar
• Zhuang H, Zhang C, Hou B. FAM83H overexpression predicts worse prognosis and correlates with less CD8(+) T cells infiltration and Ras-PI3K-Akt-mTOR signaling pathway in pancreatic cancer. Clin Transl Oncol. 2020;22:2244–2252. doi:10.1007/s12094-020-02365-z
   PubMedGoogle Scholar
• Lee JS, Park SS, Lee YK, et al. Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA. Mol Oncol. 2019;13:1623–1650. doi:10.1002/1878-0261.12537
   PubMedGoogle Scholar
• Pushalkar S, Hundeyin M, Daley D, et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov. 2018;8:403–416. doi:10.1158/2159-8290.CD-17-1134
   PubMed Web of Science ®Google Scholar
• Diakos CI, Charles KA, McMillan DC, et al. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15:e493–503. doi:10.1016/S1470-2045(14)70263-3
   PubMed Web of Science ®Google Scholar
• Savant SS, Sriramkumar S, O’Hagan HM. The role of inflammation and inflammatory mediators in the development, progression, metastasis, and chemoresistance of epithelial ovarian cancer. Cancers. 2018;10:251. doi:10.3390/cancers10080251
   PubMedGoogle Scholar
• Sun DW, An L, Lv GY. Albumin-fibrinogen ratio and fibrinogen-prealbumin ratio as promising prognostic markers for cancers: an updated meta-analysis. World J Surg Oncol. 2020;18:9. doi:10.1186/s12957-020-1786-2
   PubMed Web of Science ®Google Scholar
• Iivanainen S, Ahvonen J, Knuuttila A, et al. Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors. Esmo Open. 2019;4:e000531. doi:10.1136/esmoopen-2019-000531
   PubMed Web of Science ®Google Scholar
• Fourie C, Shridas P, Davis T, et al. Serum amyloid A and inflammasome activation: a link to breast cancer progression? Cytokine Growth Factor Rev. 2021;59:62–70. doi:10.1016/j.cytogfr.2020.10.006
   PubMed Web of Science ®Google Scholar
• Webb NR. High-density lipoproteins and serum amyloid A (SAA). Curr Atheroscler Rep. 2021;23:7. doi:10.1007/s11883-020-00901-4
   PubMedGoogle Scholar
• Takehara M, Sato Y, Kimura T, et al. Cancer-associated adipocytes promote pancreatic cancer progression through SAA1 expression. Cancer Sci. 2020;111:2883–2894. doi:10.1111/cas.14527
   PubMed Web of Science ®Google Scholar
• Yang W, Han B, Chen Y, et al. SAAL1, a novel oncogene, is associated with prognosis and immunotherapy in multiple types of cancer. Aging. 2022;14:6316–6337. doi:10.18632/aging.204224
   PubMedGoogle Scholar
• Watanabe H, Okada M, Kaji Y, et al. [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. Gan To Kagaku Ryoho. 2009;36:2495–2501. Japanese.
   PubMedGoogle Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252–7259. doi:10.1158/1078-0432.CCR-04-0713
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–867. doi:10.1038/nature01322
   PubMed Web of Science ®Google Scholar
• Yu T, Guo F, Yu Y, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell. 2017;170:548–563.e16. doi:10.1016/j.cell.2017.07.008
   PubMed Web of Science ®Google Scholar
• Malle E, Sodin-Semrl S, Kovacevic A. Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell Mol Life Sci. 2009;66:9–26. doi:10.1007/s00018-008-8321-x
   PubMed Web of Science ®Google Scholar
• Djurec M, Graña O, Lee A, et al. Saa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumors. Cancer Sci. 2018;115:E1147–e1156.
   Google Scholar
• Chan DC, Chen CJ, Chu HC, et al. Evaluation of serum amyloid A as a biomarker for gastric cancer. Ann Surg Oncol. 2007;14:84–93. doi:10.1245/s10434-006-9091-z
   PubMedGoogle Scholar
• He LN, Fu S, Zhang X, et al. Baseline and early changes in circulating Serum Amyloid A (SAA) predict survival outcomes in advanced non-small cell lung cancer patients treated with Anti-PD-1/PD-L1 monotherapy. Lung Cancer. 2021;158:1–8. doi:10.1016/j.lungcan.2021.05.030
   PubMed Web of Science ®Google Scholar
• Wood SL, Rogers M, Cairns DA, et al. Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer. Br J Cancer. 2010;103:101–111. doi:10.1038/sj.bjc.6605720
   PubMedGoogle Scholar
• Chiorean EG, Cheung WY, Giordano G, et al. Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review. Ther Adv Med Oncol. 2019;11:1758835919850367. doi:10.1177/1758835919850367
   Google Scholar
• Kim S, Signorovitch JE, Yang H, et al. Comparative effectiveness of nab-paclitaxel plus gemcitabine vs FOLFIRINOX in metastatic pancreatic cancer: a retrospective nationwide chart review in the United States. Adv Ther. 2018;35:1564–1577. doi:10.1007/s12325-018-0784-z
   PubMed Web of Science ®Google Scholar
• Riedl JM, Posch F, Horvath L, et al. Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: a propensity score analysis. Eur J Cancer. 2021;151:3–13. doi:10.1016/j.ejca.2021.03.040
   PubMed Web of Science ®Google Scholar
• Marschner N, Hegewisch-Becker S, Reiser M, et al. FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma: a novel validated prognostic score to facilitate treatment decision-making in real-world. Int J Cancer. 2022;152:458–469. doi:10.1002/ijc.34271
   PubMedGoogle Scholar
• Perera S, Jang GH, Wang Y. hENT1 expression predicts response to gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma (PDAC). Clin Cancer Res. 2022;28(23):5115–5120. doi:10.1158/1078-0432.CCR-22-2576
   PubMedGoogle Scholar
• Muckenhuber A, Berger AK, Schlitter AM, et al. Pancreatic ductal adenocarcinoma subtyping using the biomarkers hepatocyte nuclear factor-1A and Cytokeratin-81 correlates with outcome and treatment response. Clin Cancer Res. 2018;24:351–359. doi:10.1158/1078-0432.CCR-17-2180
   PubMedGoogle Scholar
• Stevens L, Pathak S, Nunes QM, et al. Prognostic significance of pre-operative C-reactive protein and the neutrophil-lymphocyte ratio in resectable pancreatic cancer: a systematic review. HPB (Oxford). 2015;17:285–291. doi:10.1111/hpb.12355
   PubMed Web of Science ®Google Scholar
• Jamieson NB, Glen P, McMillan DC, et al. Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. Br J Cancer. 2005;92:21–23. doi:10.1038/sj.bjc.6602305
   PubMed Web of Science ®Google Scholar